I'll add just a little bit. Although I think that the human BID-80 data will ultimately supersede anything preclinical, I will add that preclinical studies to date, in addition to what Al described with the cow knockout animals, has all looked remarkably benign. And so people have looked in non-human primates as well as rodent species. We've done this internally in our mouse studies that we've talked about at conferences. Other people have reported on this. And so far, reduction of cow using gene therapy or gene therapy-like approaches has seen quite remarkably benign. So you never know until you do the ultimate human experiment. But to date, things look pretty positive with regard to knockdown risk.

Aug 6, 2024 / receipt, needs a key / Al, other | earnings call 2024-08-06 | transcript a8505d43-90a8-4728-bae0-d5300948bcc6 | chars 30930-31639 | segment 31